• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

30
2
2
2
1

COUNTRY

2

PRICE

4
4
7
37

PUBLISHED

0
1
2
37

PRODUCT TYPE

34
3

Lymphoma

(37 Products)

Lymphoma encompasses a variety of blood cancers of the lymphatic system. Non-Hodgkin’s Lymphoma (NHL) for example, is diagnosed in over 100,000 every year in the US and EU combined. An array of expert reports in our Lymphoma Section enable you to investigate drug development strategies and market trends for NHL, Hodgkin’s Lymphoma, Skin Lymphoma, T-Cell Lymphoma, Indolent Lymphoma and other variants. Investigate key issues such as licensing, R&D, industry alliances, generic drugs (rituximab, bortezomib, doxorubicin, bleomycin, vinblastine, etc.) and the activities of major pharmaceutical players such as Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Show Less Read more

Lymphoma Drug Pipeline Update 2015

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today 339 companies plus partners developing 464 lymphoma drugs in 884 developmental projects in cancer....

June 2015
FROM

Lymphoma Drug Pathway Analyzer 2015

Extra value: One year of free online updates included with this product There are today at least 391 targeted molecular therapies known to affect more than 243 specific intracellular signaling pathways...

January 2015
FROM

Analytical Tool - Lymphoma

Executive Summary "Analytical Tool: Lymphoma" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphoma R&D and business development. It is also a map...

March 2014

Triple Analysis: Lymphoma, Melanoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according...

June 2013
FROM

Triple Analysis: Lung Cancer, Lymphoma and Melanoma

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

June 2013
FROM

Non-Hodgkin Lymphomas: Advanced Diagnostics and Personalized Therapies

This book presents the most recent advances in the areas of advanced diagnostics and treatment of lymphoma. Success in matching patients with effective and safe novel targeted therapy depends on standardized...

June 2013

Triple Analysis: Lymphoma, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

January 2013
FROM

Triple Analysis: Colorectal Cancer, Lymphoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

November 2012
FROM

Triple Analysis: Leukemia, Lymphoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

November 2012
FROM

Triple Analysis: Lymphoma, Apoptosis and Antibodies

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies)....

November 2012
FROM

Triple Analysis: Lung Cancer, Lymphoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

November 2012
FROM

Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

September 2012
FROM

Triple Analysis: Lymphoma, Prostate Cancer and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

September 2012
FROM

Triple Analysis: Breast Cancer, Lung Cancer and Lymphoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Lymphoma. Each of these three individual parts is evaluated according to standardized criteria in...

August 2012
FROM

Triple Analysis: Breast Cancer, Lymphoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

August 2012
FROM

Triple Analysis: Lymphoma, Apoptosis and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual...

May 2012
FROM

Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts...

May 2012
FROM

Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria...

March 2012
FROM

Triple Analysis: Lymphoma, Pancreatic Cancer and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

March 2012
FROM

Triple Analysis: Lymphoma, Apoptosis and Angiogenesis

This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Each of these three individual parts is evaluated...

January 2012
Loading Indicator

Our Clients

Takeda Pharmaceutical Company Limited GlaxoSmithKline PLC Accuray Incorporated Becton, Dickinson and Company (BD) Novartis AG Elekta AB